Company intelligence / Profile preview
SOTIO Biotech
- Ownership
- Private
- Development stage
- Other
Overview
SOTIO Biotech is conducting multiple early-phase (Phase 1/2) clinical trials of novel immunotherapies and ADCs for cancer, including an IL-15 superagonist-PD-1 immunocytokine (SOT201), a CAR-T cell therapy targeting GPC3 (BOXR1030), and several targeted ADCs at various clinical and preclinical stages. The company is actively expanding its pipeline via in-house research and external collaborations, with promising early clinical data and new programs entering the clinic since 2023–2024[1][3][4].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateCAR-T cell therapyCell therapyImmunocytokineSmall moleculeBiologicDendritic cell therapy
- Industry
- Biotech
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on SOTIO Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOTIO Biotech.